NASDAQ:MNOV - MediciNova Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.82 -0.01 (-0.11 %) (As of 12/12/2018 05:50 AM ET)Previous Close$8.83Today's Range$8.69 - $9.0152-Week Range$6.09 - $14.50Volume40,500 shsAverage Volume161,442 shsMarket Capitalization$376.51 millionP/E Ratio-27.56Dividend YieldN/ABeta0.78 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California. Receive MNOV News and Ratings via Email Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV Previous Symbol CUSIPN/A Webmedicinova.com Phone858-373-1500 Debt Debt-to-Equity RatioN/A Current Ratio34.89 Quick Ratio34.89 Price-To-Earnings Trailing P/E Ratio-27.56 Forward P/E Ratio-20.51 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book8.24 Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-11,160,000.00 Net MarginsN/A Return on Equity-24.40% Return on Assets-23.07% Miscellaneous Employees9 Outstanding Shares41,880,000Market Cap$376.51 million OptionableOptionable MediciNova (NASDAQ:MNOV) Frequently Asked Questions What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) posted its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History. When is MediciNova's next earnings date? MediciNova is scheduled to release their next quarterly earnings announcement on Monday, December 17th 2018. View Earnings Estimates for MediciNova. What price target have analysts set for MNOV? 1 equities research analysts have issued 12-month price targets for MediciNova's stock. Their predictions range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next year. This suggests a possible upside of 149.4% from the stock's current price. View Analyst Price Targets for MediciNova. What is the consensus analysts' recommendation for MediciNova? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova. Has MediciNova been receiving favorable news coverage? News coverage about MNOV stock has trended positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MediciNova earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the immediate future. Who are some of MediciNova's key competitors? Some companies that are related to MediciNova include Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Mirati Therapeutics (MRTX), Tricida (TCDA), Myovant Sciences (MYOV) and Insmed (INSM). Who are MediciNova's key executives? MediciNova's management team includes the folowing people: Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 50)Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)Mr. Geoffrey G. O'Brien, VP & Exec. Officer (Age 49)Ms. Carla Reyes, Chief Financial Officer (Age 46) Who are MediciNova's major shareholders? MediciNova's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.75%), Vanguard Group Inc. (3.78%), FMR LLC (0.99%), Bridgeway Capital Management Inc. (0.32%), TIAA CREF Investment Management LLC (0.18%) and Alps Advisors Inc. (0.18%). Company insiders that own MediciNova stock include Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova. Which major investors are selling MediciNova stock? MNOV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Virtus ETF Advisers LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for MediciNova. Which major investors are buying MediciNova stock? MNOV stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., BlackRock Inc., Vanguard Group Inc., Alps Advisors Inc., Alliancebernstein L.P., MetLife Investment Advisors LLC and Jane Street Group LLC. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova. How do I buy shares of MediciNova? Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $8.82. How big of a company is MediciNova? MediciNova has a market capitalization of $376.51 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. MediciNova employs 9 workers across the globe. What is MediciNova's official website? The official website for MediciNova is medicinova.com. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]ova.com. MarketBeat Community Rating for MediciNova (NASDAQ MNOV)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 139 (Vote Outperform)Underperform Votes: 96 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?